Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity
Journal of Hematology & Oncology volume 15, Article number: 172 (2022)
Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes. Thus, it is crucially important to identify genetic interactions between genes that are significantly mutated in cancer patients and those involved in immune responses, ideally the ones that currently have chemical compounds for direct targeting. To systematically interrogate such genetic interactions that mediate cancer cells’ response to T cell killing, we designed an asymmetric dual perturbation library targeting the matched combinations between significantly mutated tumor suppressors and immune resistance genes. We performed a combinatorial double knockout screen on 1159 gene pairs and identified those where joint loss-of-function renders altered cellular response to T cell cytotoxicity. We also performed comparative transcriptomics-based analyses on tumor and normal samples from TCGA and GTEx cohorts, mutational profiling analyses, and survival analyses to further characterize the significance of identified hits in clinical patients. Interactions between significantly mutated tumor suppressors and potentially druggable immune resistance genes may offer insights on potential new concepts of how to target clinically relevant cancer mutations with currently available agents. This study also provides a technology platform and an asymmetric double knockout library for interrogating genetic interactions between cancer mutations and immune resistance pathways under various settings.
To the editor,
Despite impressive durable responses elicited by cancer immunotherapy, the majority of patients do not see long-term benefit with treatment [1, 2]. However, the molecular mechanisms that determine therapeutic resistance remain poorly understood, particularly genetic interactions. To systematically interrogate such genetic interactions that mediate immune resistance, we designed a Combinatorial Antineoplastic Drug Resistance Experiment (CADRE) screening strategy with an asymmetric library design (Fig. 1A, B). The CADRE library was synthesized via oligonucleotide array and cloned into lentiviral vectors (Additional file 1: Fig. S1A), and the representations of double knockouts (DKOs), single knockouts (SKOs), and double non-targeting controls (DNTCs) in the library were verified by next-generation sequencing (NGS) (Additional file 1: Fig. S1C, D). We transduced B16F10;OVA;Cas9 cells at a low multiplicity of infection (MOI) (MOI < 0.2) at a coverage of approximately 500X. We NGS verified that the transduced pre-selection cell pool retained the vast majority of the CADRE library (Additional file 1: Fig. S1E).
We then performed co-culture assays on library and non-library infected B16F10;OVA;Cas9 clone #3 cells (BC3 cells) with OT-I CD8 + T cells. Both library and non-library transduced cells showed comparable survival across E:T ratios, with the exception of at the high E:T ratio conditions (E:T ratios > 1) where the mutant pool demonstrated a significant increase in resistance (Fig. 1C). We then performed the co-culture screen with BC3-CADRE cells and OT-I CD8 + T-cells, followed by library NGS readout (Additional file 1: Fig. S2A). Clustering analysis showed distinct clusters between plasmid, cell populations before co-culture, and cell populations post co-culture (Additional file 1: Fig. S2B), suggesting a high-quality screen and NGS readout between the cell pool conditions and E:T ratios 2–5 (Fig. 1D). There are strong shifts between pre-selection and post-selection co-cultures (Additional file 1: Fig. S2C), indicative of strong selection seen at sgRNA library levels.
At a false-discovery rate (FDR) of 1.19% we identified 222 enriched sgRNA pairs of which 194 (87.4%) are associated with Janus kinase 1 (Jak1) or Janus kinase 2 (Jak2), including DKO and SKO constructs. Bulk analysis revealed that Jak-associated sgRNAs dominated the enrichment in the screen post-selection (Fig. 1E; Additional file 1: Fig. S3A–D). We found that Jak1/2-associated gene pairs were the most statistically significantly different from their constitutive SKOs (Fig. 1E, F; Additional file 1: Fig. S3E, F), suggestive of potential gene interactions. We observe that gene pairs Jak1_Trp53, Jak1_Nf1, and Jak1_Rb1 have higher observed enrichment for double knockout than expected (adjusted p-value < 0.001) suggesting potential additive gene interaction (Fig. 1F), while gene pairs Jak1_Apc, Jak1_Vhl, Jak1_Kmt2c, Jak1_Kmt2d, Jak1_Arid1a, Jak1_Fbxw7, Jak1_Ctnnb1 have lower observed enrichment for double knockout than expected, suggesting potential subtractive gene interaction (Fig. 1F). Boxplots of normalized read counts for Jak1_Kmt2d, Jak2_Kmt2d, Jak1_Trp53 and Jak2_Trp53 (Fig. 2A–D) also suggest potential subtractive and additive phenotypic interactions to Jak1/2 perturbation for Kmt2d and Trp53, respectively. However, it should be noted that although significant, the putative gene interaction signals appear to be modest in part due to the strong resistance phenotype of single knockout of JAK1/2.
We looked at the global gene expression profiles of KMT2D, JAK1, TP53, and IFNGR1 across all tumor samples and paired normal tissues (Additional file 1: Fig. S4A–D) and more specifically for KMT2D and JAK1 in the SKCM cohort (Fig. 2E–G) and identified tumor-type specific expression patterns. We found that the effector and exhaustion T cell signatures were upregulated in the tumor samples in melanoma patients (Fig. 2G). Cell proportion deconvolution analyses revealed increased estimated proportions of CD8 T cells, memory-activated CD4 T cells, and Tregs in the tumor samples, with a decrease of naïve and memory resting CD4 T cells (Fig. 2H).
Genes negatively correlated with KMT2D were further analyzed using DAVID gene ontology functional annotation (Fig. 2F). We found positive and significant correlations for both JAK1 and IFN-gamma signaling gene signatures across both the SKCM cohort and across 33 different cancer types from TCGA (Additional file 1: Fig. S5A). KMT2D and JAK1 are both frequently mutated in melanoma patients (Additional file 1: Fig. S5B). Mutual exclusivity and co-occurrence analyses for all pairwise combinations of KMT2D, JAK1, JAK2, IFNGR1, and TP53 suggest that all mutation combinations except JAK2-IFNGR1 co-occur at a significant rate (Additional file 1: Fig. S5C).
We also performed survival analyses on patient cohorts with the public database TCGA (The Cancer Genome Atlas) (Additional file 1: Figs. S4E, F, S5D, E). Survival maps (Additional file 1: Fig. S4G, H) revealed cancer-type specific effects of KMT2D, JAK1, JAK2, IFNGR1, or TP53 expression levels on patient survival. The KMT2D-low patient group demonstrated increased CTL-associated overall survival benefit, whereas high levels of KMT2D abolished the overall survival benefit of CTL-high patients (Fig. 2I).
Altogether, we demonstrate how dual loss-of-function CRISPR screens with asymmetric library designs can resolve complex phenotypes such as resistance to T cell killing.
Availability of data and materials
All data generated or analyzed during this study are included in this article and its Additional files. Specifically, source data and statistics for non-high-throughput experiments are provided in Additional file 2: Tables and Datasets. Processed data for high-throughput sequencing experiments are provided as processed quantifications in Additional file 2: Tables and Datasets. Raw sequencing data is available via SRA/BioProject under accession number PRJNA661532. Original cell lines are available at commercial sources listed in Additional files. Genetically modified cell lines are available via Chen lab. Most data, reagents, methods, computational codes and materials that support the findings of this research are available from the corresponding author upon reasonable request.
- BC3 cells:
B16F10;OVA;Cas9 clone #3 cells
Combinatorial antineoplastic drug resistance experiment
Significantly mutated gene
Loss of function
Genetically engineered mouse model
Cytotoxic T lymphocyte
Immune checkpoint blockade
Tumor immune dysfunction and exclusion
Database for annotation, visualization and integrated discovery
The cancer genome Atlas
Skin cutaneous melanoma
Double non-targeting control
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.
Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med. 2019;25:389–402.
We thank all members in Chen laboratory, as well as various colleagues in Department of Genetics, Systems Biology Institute, Cancer Systems Biology Center, MCGD Program, Immunobiology Program, BBS Program, Cancer Center, Stem Cell Center, Liver Center, RNA Center and Center for Biomedical Data Sciences at Yale for assistance and/or discussion. We thank the Center for Genome Analysis, Center for Molecular Discovery, High Performance Computing Center, West Campus Analytical Chemistry Core, and Keck Biotechnology Resource Laboratory at Yale, for technical support.
SC is supported by Yale SBI/Genetics Startup Fund, NIH/NCI/NIDA (DP2CA238295, 1R01CA231112, U54CA209992-8697, R33CA225498, RF1DA048811), DoD (W81XWH-17-1-0235), Damon Runyon Dale Frey Award (DFS-13-15), Melanoma Research Alliance (412806, 16-003524), St-Baldrick’s Foundation (426685), Breast Cancer Alliance, Cancer Research Institute (CLIP), AACR (499395, 17-20-01-CHEN), The Mary Kay Foundation (017-81), The V Foundation (V2017-022), Ludwig Family Foundation, Blavatnik Family Foundation, Sontag Foundation (DSA), Chenevert Family Foundation, ACGT, PSSCRA, Yale Cancer Center (Team Science Award), and Dexter Lu Gift. JJP is supported by the Yale MSTP training grant from NIH (T32GM007205). AC is supported by Yale PhD training grant from NIH (T32GM007499) and Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (F31 Diversity, F31CA236453).
Ethics approval and consent to participate
This study has received institutional regulatory approval. All recombinant DNA and biosafey work was performed under the guidelines of Yale Environment, Health and Safety (EHS) Committee with an approved protocol (Chen-rDNA-15–45; Chen-rDNA-18-45). All animal work was performed under the guidelines of Yale Institutional Animal Care & Use Committee (IACUC) with an approved protocol (Chen-2018-20068).
Consent for publication
No competing interest related to this study. SC is a (co)founder of EvolveImmune Tx, Cellinfinity Bio, Chen Consult, Chen Tech, all unrelated to this study.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Park, J.J., Codina, A., Ye, L. et al. Double knockout CRISPR screen for cancer resistance to T cell cytotoxicity. J Hematol Oncol 15, 172 (2022). https://doi.org/10.1186/s13045-022-01389-y